Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

C. W. Hong; S. K. Libutti; B. J. Wood

doi:10.3747/co.20.1266

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

C. W. Hong, S. K. Libutti, B. J. Wood

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

Original language	English (US)
Pages (from-to)	274-277
Number of pages	4
Journal	Current Oncology
Volume	20
Issue number	3
DOIs	https://doi.org/10.3747/co.20.1266
State	Published - 2013
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology

Keywords

Ablation
Doxorubicin
Hepatocellular carcinoma
Liposomes
RFA

Access to Document

10.3747/co.20.1266

Cite this

@article{fcf25a6febd34a368cccee14a9786d8b,

title = "Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma",

abstract = "Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.",

keywords = "Ablation, Doxorubicin, Hepatocellular carcinoma, Liposomes, RFA",

author = "Hong, {C. W.} and Libutti, {S. K.} and Wood, {B. J.}",

year = "2013",

doi = "10.3747/co.20.1266",

language = "English (US)",

volume = "20",

pages = "274--277",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "3",

}

TY - JOUR

T1 - Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

AU - Hong, C. W.

AU - Libutti, S. K.

AU - Wood, B. J.

PY - 2013

Y1 - 2013

N2 - Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

AB - Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

KW - Ablation

KW - Doxorubicin

KW - Hepatocellular carcinoma

KW - Liposomes

KW - RFA

UR - http://www.scopus.com/inward/record.url?scp=84878764831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878764831&partnerID=8YFLogxK

U2 - 10.3747/co.20.1266

DO - 10.3747/co.20.1266

M3 - Article

C2 - 23737698

AN - SCOPUS:84878764831

SN - 1198-0052

VL - 20

SP - 274

EP - 277

JO - Current Oncology

JF - Current Oncology

IS - 3

ER -

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this